Why the study?
Does sFRP2 antibody blockade improve cardiac function and reduce fibrosis in cardiomyopathic hamsters?
Population
Cardiomyopathic hamsters
Comparison
sFRP2 antibody vs Saline and IgG control
Design
Preclinical
Follow-up
1 month
Authors
Loading...
May support sFRP2 blockade in experimental cardiomyopathy; hypothesis-generating and leaves open human translation.
Does sFRP2 antibody blockade improve cardiac function and reduce fibrosis in cardiomyopathic hamsters?
Antibody-based blockade of sFRP2 improves cardiac function and reduces myocardial fibrosis in a cardiomyopathic hamster model, highlighting it as a potential therapeutic target for heart failure.
Mastri et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: